forex,euro,dollar,binary option,btc,usd,oil
Continued progress advancing next-generation antibody portfolio, with ongoing clinical trials evaluating the broad potential of SRF388 and SRF617 across multiple tumor types Company continues to guide to cash runway through 2023 CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) — Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, …
The post Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021 appeared first on ForexTV.
The post Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021 appeared first on Forex news – Binary options.